Main Conference Day 2 - Oct 22, 2025Wednesday, 22 October 2025 - JT (Japan Time, GMT+09:00)

Fibrosis can affect multiple organs in the human body and significantly threaten human health. Early diagnosis and intervention are crucial for preventing disease progression. However, very few treatments are available to patients. Next-generation medications with novel mechanisms of action are demanded to broaden the responding patient population and improve the therapeutic index. WNT1-inducible signaling pathway protein 1 (WISP1, also known as CCN4), a matricellular protein, was identified as a novel drug target for fibrosis through analysis of the transcriptomic data of human cirrhotic livers. I will present the preclinical studies of targeting WISP1 for treating tissue fibrosis.

Biocytogen provides a unique, fully characterized library of fully human antibody binders targeting over 1,000 druggable proteins. Several bispecific ADC assets, utilizing a common light chain and our proprietary Top1 payload, are now in clinical trials. RenNano mice generate fully-human nanobodies for next-generation ADC.

Despite advances in cancer therapeutics, new protein targets and targeting approaches for drug development are needed. We developed a high-resolution proximity proteomics technology using photocatalyst-generated reactive probes to label discrete cell surface protein microenvironments. Combined with quantitative mass spectrometry, we characterize plasma membrane protein interactomes and integrate proximity proteomics data with clinical protein expression profiles through computational graphs and graph convolutional neural networks (GCNNs). This membrane interactomics (MInt) database enables the unbiased identification of inherently proximal surface antigens in tumor microenvironments and facilitates precise dual-targeting of malignant cells. Utilizing our platform to identify proteins inherently proximal to EGFR on tumor cells, we identified CDCP1 as a TAPA (tumor associated proximity antigen) of interest. Our findings led to the development of IDP-001, a novel bispecific ADC targeting EGFR and CDCP1, anticipated to enter clinical trials in 2026. Identification and characterization of IDP-001 will be presented.

For more information about presenting in this session, please contact Michael Keenan at Michael.Keenan@informa.com